Table 5. Study comparison with recent prospective studies of ENKTL.
| Author, year | Disease status | No. Of patients | Treat | CR rate | Survival | |
|---|---|---|---|---|---|---|
| OS | PFS | |||||
| Mingzhi zhang et al. 2015 (this study) | Newly- diagnosed | Stage III/IV: 25 | DDGP | 70.83% | 79.20% (1-yr) 68.50% (2-yr) |
75.00% (1-yr) 61.80% (2-yr) |
| Lin et al. 2013 | Newly- diagnosed | Stage I/II: 30 Stage III/IV: 6 |
CHOP-L ± RT | 90% 50% |
88.3% (2-yr) 50% (2-yr) |
89.5% (2-yr) 50% (2-yr) |
| Wang L, et al. 2013 | Newly -diagnosed | Stage IE/IIE: 27 | GELOX± RT | 74.1% | 86% (2-yr) | 86% (2-yr) |
| Kwong YL, et al. 2012 | Newly-diagnosed Relapse/refractory |
Newly diagnosed Stage I/II:17 Stage IV: 26 relapse/refractory: 44 |
SMILE | 66% | Newly diagnosed 47.4% (5-yr) |
Newly diagnosed 60.0% (4-yr) |
| Yamaguchi M, et al. 2011 | Newly-diagnosed Relapse/refractory |
Newly-diagnosed Stage IV: 20; relapse/refractory: 18 |
SMILE | 45% | 55% (1-yr) | --- |
| Jaccard et al. 2011 | Relapse/refractory | 19 | AspaMetDex | 61% | --- | Median PFS: 12.2 months |